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Chronic kidney disease is assuming epidemic proportions,
and an increasing number of clinical trials are testing
treatments developed to improve morbidity and mortality.
Surprisingly, however, a large proportion of these trials have
had negative or neutral results. When trials unexpectedly
demonstrate either no benefit or a detrimental impact of
a treatment, especially when that treatment is already used
in practice, critics commonly argue that the results were
dictated by flawed trial design rather than the intrinsic
properties of the treatment. In kidney disease therapeutics,
trials commonly rely on observational data and test the
hypothesis that these associations may be extrapolated to
cause-and-effect. Other key issues in trial design that may
affect outcomes include the impact of enrolling relatively
healthier subjects, the complexity of recruiting participants
with specific characteristics while maintaining
generalizability, and the subtleties of event adjudication and
quality of life assessments. In this article, general principles
of trial design will be discussed and the potential lessons
learned from recent trials in nephrology will be critically
reviewed.
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Chronic kidney disease (CKD) and end-stage renal disease
(ESRD) are complex, chronic conditions that affect nearly
17% of the US population.1 Extensive basic and clinical
research has been conducted during the past several decades
to improve the often dismal outcomes in patients with these
conditions. Although results from laboratory investigations,
observational studies, and clinical trials in populations other
than those with CKD and ESRD have often suggested
promising therapeutic approaches, a growing list of rando-
mized controlled trials in nephrology have not rejected their
null hypotheses or have had rather counterintuitive and
unexpected negative results. For example, the Correction of
Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)
and Cardiovascular Risk Reduction by Early Anemia Treat-
ment with Epoetin Beta (CREATE) trials did not show a
benefit of greater anemia correction in a CKD population;
the Hemodialysis Study (HEMO) and Adequacy of Peritoneal
Dialysis in Mexico trials did not support the aggressive
removal of small solutes from ESRD patients; and the
German Diabetes and Dialysis Study (Die Deutsche Diabetes
Dialyse Studie, 4D) did not demonstrate improved outcomes
with atorvastatin in hemodialysis (HD) patients with
diabetes mellitus.2–6
Why have there been so many trials in nephrology that
have failed to reject their null hypotheses? There are at least
two possibilities: first, the null hypothesis is true (that is,
the treatment does not result in the anticipated benefit);
and second, subtleties in trial design affected comparison
of outcomes. Our goal in this review is not to criticize
individual trials, but to raise points for discussion about
potential methodological ‘lessons learned.’ This review is
organized to follow the natural progress in the design of a
clinical trial to include the formulation of the clinical
question, the designation of the study population and basic
trial design, subject recruitment, detection of end points, and
assessment of quality of life (QOL)7 (Table 1).
THE CLINICAL QUESTION
Reliance on observational data
Most large clinical trials in nephrology and other disciplines
are designed on the basis of the results of observational
studies. For instance, with respect to anemia management,
a wealth of data from numerous countries indicated that
increasing hemoglobin (Hb) in both CKD and ESRD patients
was associated with lower all-cause and cardiac mortality,
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lower rate and length of hospitalization, and lower health-
care expenditures.8–12 These reports strongly suggested that
the treatment of anemia with erythropoiesis-stimulating
agents is associated with lower cardiovascular morbidity
and mortality.13,14
On the basis of these studies, randomized controlled
trials were performed to test the hypothesis that anemia
correction to higher levels with erythropoiesis-stimulating
agents improves cardiovascular outcomes. The Normal
Hematocrit study randomized 1265 ESRD patients with
congestive heart failure (CHF) or ischemic heart disease to
epoetin alfa dosed to achieve a hematocrit of either 30 or
42%.15,16 The trial was halted early when the high-hematocrit
group was noted to have a trend toward increased mortality
and nonfatal myocardial infarction (MI) that approached
statistical significance (interim report, relative risk (RR) 1.3;
95% confidence interval (CI) 0.9–1.9 and final data set,
RR 1.3, 95% CI 0.9–1.8). Similarly, CHOIR randomized
1432 patients with CKD (estimated glomerular filtration
rate (GFR) 15–50 ml/min/1.73 m2) to epoetin alfa dosed to
a target Hb 11.3 versus 13.5 g/100 ml (ref. 5). This trial,
too, was stopped early by the Data Safety Monitoring
Board.17 The final results demonstrated a greater risk of the
overall end point of death, CHF hospitalization, stroke, and
MI in the group randomized to the higher Hb target (hazard
ratio (HR) 1.34; 95% CI 1.03–1.74).5 Finally, CREATE
randomized 603 patients with CKD (estimated GFR
15–35 ml/min/1.73 m2) to epoetin beta dosed for a target
Hb 10.5–11.5 versus 13–15 g/100 ml. This trial went to
completion with no difference in cardiovascular events
between groups (HR 0.78; 95% CI 0.53–1.14) but a higher
rate of dialysis initiation (42 versus 37%, P¼ 0.03) and
hypertension (30 versus 20%, P¼ 0.005) in the group
randomized to the higher Hb target.2 The significantly worse
event rate in CHOIR, compared with CREATE, may be
explained by (1) the inclusion of twice as many diabetics
(49 versus 26%) with three times the mortality rate
(29 versus 9%) and (2) the enrollment of over twice as
many total patients, plausibly with greater power to detect a
difference in the primary end point.
Clearly, the randomized data did not confirm and, in fact,
refuted the conclusions that nephrologists drew from the
observational data. These results have subsequently been the
subject of much speculation, with hypotheses including high-
dose erythropoiesis-stimulating agent toxicity, innate resis-
tance of some patient populations to erythropoiesis-stimu-
lating agent, increased use of intravenous iron, and decreased
Kt/V (in ESRD patients) in the high-Hb/hematocrit groups.
Additionally, it has been suggested that some underlying
factor(s) causing the anemia, not the anemia itself, is
detrimental.2 Regardless of the underlying mechanism,
these trials did not show that complete correction of anemia,
which seemed practically axiomatic from the observational
data, improved outcomes. What lessons can be learned from
this example? Certainly not that it is inappropriate to
generate hypotheses based on multiple, consistent observa-
tional studies. One lesson, as applied to individual clinical
scenarios, might be that observational data need to be
confirmed in the vast majority of clinical scenarios in a
randomized trial design. The potential for and significance of
uncontrolled and under-recognized confounding in patients
with CKD and ESRD cannot be underscored enough.
Extrapolation of results from other populations
As therapeutic trials typically have limited the number of
patients with CKD, clinical practice has often moved forward
based on extrapolation from therapeutic success in the
broader patient population and secondary post hoc analyses
of subgroups of CKD patients in these trials. Only later, if at
all, have trials been done to attempt to confirm this
extrapolation in a prospectively designed clinical trial with
adequate power within the CKD population. As an example,
the 4D trial randomized 1255 subjects with diabetes mellitus
and ESRD to either 20 mg/day of atorvastatin or placebo.6
Prior to that trial, several different statins had been shown to
reduce cardiovascular events by 20–30% in patients with type
2 diabetes without CKD.18–20 Given the high cardiovascular
event rate in patients with ESRD and the demonstrated
efficacy of statins in the general population, it was hypo-
thesized that patients with ESRD should have a similar
Table 1 | Summary of clinical trial design problems, examples, and possible solutions
Step in design
Randomized clinical
trial example Problem Solution
Clinical question CHOIR, CREATE Limitations of observational data for study
design
Use clinical trial data from other fields, if available
4D Extrapolation from general population Use CKD/ESRD population data, if available
Study population MDRD Healthy volunteer bias Enroll a more representative sample
HEMO Selection bias Enroll a more representative sample
Basic study design Treat to Goal Paired outcome analysis Avoid nonmortality comparisons
NECOSAD Insufficient enrollment Revise inclusion/exclusion criteria
Choice and detection
of end points
CHF, GFR Wide variability in end-point definition Standardize end-point definitions
Assessment of QOL ESRD High prevalence of psychiatric illness Avoid over-interpretation
CHF, congestive heart failure; CHOIR, Correction of hemoglobin and outcomes in renal insufficiency; CKD, chronic kidney disease; CREATE, cardiovascular risk reduction by
early anemia treatment with epoetin beta; 4D, Die Deutsche Diabetes Dialyse Studies; ESRD, end-stage renal disease; GFR, glomerular filtration rate; HEMO, hemodialysis
study; MDRD, modification of diet in renal disease; NECOSAD, Netherlands cooperative study on the adequacy of dialysis.
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benefit. As would be expected, rates of MI or death from
coronary heart disease in 4D was reportedly the highest of
any trial of statin therapy, reflecting this high incidence of
cardiovascular disease in the ESRD population. However,
despite lowering the low-density lipoprotein concentration
from 127 to 72 mg/100 ml, atorvastatin produced only a
modest decrease in the primary end point of cardiac death,
nonfatal MI, and stroke (RR 0.92; 95% CI 0.77–1.10).
This negative or neutral result may reflect a phenomenon
encountered in nephrology and somewhat erroneously
labeled as ‘reverse epidemiology.’ In ESRD and advanced
CKD patients, in contrast to those with normal kidney
function, higher low-density lipoprotein, triglycerides, and
total cholesterol are often associated with lower mortal-
ity.21–23 Other risk factors, such as hyperhomocysteinemia
and obesity, also have protective associations with outcomes
in the ESRD population.24,25 In many of these reports, the
expected association of these risk factors with poor outcomes
is restored by adjusting for nutritional and inflammatory
markers. These findings are thought to reflect the adverse
effects of the malnutrition–inflammation–cachexia syndrome
rather than any protective effects of hyperlipidemia, hyper-
homocysteinemia, or obesity themselves. Thus, ‘reverse
epidemiology’ is merely routine confounding with an
association not seen with the general population. While
these data and the results of 4D suggest that the pathogenesis
of cardiovascular disease in the ESRD and the general popu-
lations may be quite different (for example, ESRD patients
experience accelerated medial arteriosclerosis, whereas non-
CKD patients classically develop intimal atherosclerosis26),
they may also suggest the need to carefully consider the
features of the trials in subjects with normal kidney function
in the design of a trial in ESRD. Hence, treatments effective
for one group may not be effective for the other. Specifically,
in this example, does a single level of statin dosing or a single
threshold for low-density lipoprotein lowering confer the
same risk or benefit in a cachectic patient with ESRD as it
does in a nutritionally replete ESRD patient or a nutritionally
replete patient with normal kidney function? If the asso-
ciations that affect ESRD and CKD patients are different
from those of the general population, these differences
should be reflected in a careful reexamination of the trial
design as we move from one population to another. Further,
it may not be appropriate to assume that the time course of
benefit in the general population will be replicated in the
population with ESRD.
The 4D study illustrates another lesson inherent in the
ESRD and CKD populations: the potential for a low signal-
to-noise ratio. At first glance, ESRD patients with diabetes
mellitus appear ideally suited to test the effect of statins on
cardiovascular mortality. In the United States Renal Data
System (USRDS), ESRD patients have a sevenfold higher
mortality rate than the collective Medicare cohort over age 65
(357 versus 51.5 deaths per 1000 patient-years, respectively),
and heart disease alone claims 120–130 lives per 1000 patient-
years among ESRD patients with diabetes.27 While the rate of
death due to cardiac causes in 4D was somewhat lower, being
54 deaths per 1000 patient-years (see ‘The Study Population’
below), the authors noted that sudden cardiac death, an end
point that they felt, a priori, would not be affected by statin
treatment, accounted for approximately 60% of the observed
cardiovascular mortality.28,29 It is noteworthy that secondary
analysis showed that atorvastatin treatment did reduce the
rate of all cardiac events combined, including nonfatal MI
and revascularization (RR 0.82; 95% CI 0.68–0.99).6 Perhaps
the ‘noise’ of sudden cardiac death, a frequent outcome
potentially not improved by atorvastatin treatment, may
have overwhelmed the ‘signal’ of ischemic coronary events
that were affected by atorvastatin. Whether ongoing statin
treatment can modify outcomes from certain types of
ischemic acute coronary syndromes is not clear,30,31 but is
supported to some extent by 4D. More broadly, the high rate
of cardiac death in CKD and ESRD patients, compared with
subjects with normal renal function, is likely comprised of a
heterogeneous mix that deserves tremendous scrutiny at the
stage of trial design, when expected differences between
treatment groups is proposed. This heterogeneity could mask
beneficial effects of therapy.
THE STUDY POPULATION
During trial enrollment, the potential to inadvertently recruit
patients or subjects who are healthier and more motivated
than individuals in the overall population to which one
would like to generalize results (healthy volunteer bias) is a
well-known phenomenon. Contributing to this possibility,
many trials deliberately exclude subjects with comorbidities
that would limit lifespan and subsequent power (for example,
expected lifespan o6 months). Although this practice is
appropriate to limit patient heterogeneity as described above,
if subjects in the sample are not as ‘sick’ as those in the
original population, event rates may be underestimated and
the study may be underpowered to detect a benefit of therapy
(type II error). Given the unfortunate severely shortened life
expectancies of patients with kidney disease, exclusion
criteria such as this may subjectively disqualify a larger
proportion of the population than truly appreciated in the
design phase.
A potential example of the former is the Modification
of Diet in Renal Disease Study (MDRD), which consisted of
two trials to investigate whether dietary protein restriction
in CKD patients could slow the rate of decline of GFR.32 In
study A, 585 subjects with GFR 22–55 ml/min/1.73 m2 were
randomized to receive a usual or low-protein diet (1.3 or
0.58 g protein/kg body weight/day, respectively). Study B
assigned 255 subjects with GFR 13–24 ml/min/1.73 m2 to a
low- or very low protein diet (0.58 or 0.28 g protein/kg body
weight/day, respectively). The effect of a low- or very low
protein diet was not significant in either group: the mean
decline in GFR was 1.2 ml/min over 3 years less in the low-
protein compared with the usual diet group (study A, 95% CI
1.1 to 3.6) and 0.8 ml/min/year less in the very low compared
to the low-protein group (study B, 95% CI 0.1 to 1.8).
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Although MDRD was powered to detect a difference of
30% in the rate of decline in GFR with dietary protein
restriction, the authors noted that the power to detect this
difference was weakened by a slower loss of GFR than expected
(3.8 instead of 6.0 ml/min/year).32,33 Subsequent analysis
revealed that subjects recruited for the study did not
demonstrate evidence of progressive renal disease, and 15%
of those in the study A control arm had no evidence of
GFR loss whatsoever, thus undermining the ability of the trial
to observe any effect on rates of GFR decline.34 The slower loss
of GFR may also have been due to (1) the exclusion of
diabetics, who may have benefited from dietary protein
restriction; (2) the inclusion of 200 patients with autosomal
dominant polycystic kidney disease, who did not show
benefit; and (3) the low proportion (15%) of black patients
in the sample, who had a significantly faster decline in GFR
than the remaining patients (19 versus 11 ml/min/3 years,
P¼ 0.02).32,35,36 Finally, post hoc analysis indicated that dietary
protein restriction may have been beneficial in certain
subgroups within the MDRD sample (that is, those with
faster rates of GFR loss or high-grade baseline protein-
uria).33,34 Thus, recruitment of subjects with more risk factors
for GFR loss might have produced quite different results.
The generalizability of the results may be heavily
influenced by the demographics of the subjects enrolled,
which is in turn dependent on the diversity of site selection.
In the HEMO study, 1846 subjects were recruited from
72 dialysis units at 15 clinical centers.3 Although a high
number of centers should arguably enhance generalizability
by allowing for the inclusion of multiple geographical and
practice pattern factors, such an outcome may not have
occurred in this instance. Notably, the participants in the
HEMO study were 63% African-American, compared with
32–33% in the USRDS sample of ESRD patients for the
same period, indicating a potential geographical influence
on recruitment due to site selection.27 In addition, subjects
were also relatively young (HEMO mean age 57.6±14.0
versus USRDS median age 64.5 years) and were neither
obese (mean dry weight 69.2±14.7) nor malnourished
(mean albumin 3.6±0.4 g/100 ml).37,38 Although it is not
likely in this example that a different selection of sites would
have impacted study outcome, the principle should always
be considered in the design of a trial and site selection.
On the other hand, some trials have results severely
affected by insufficient enrollment. For example, the Nether-
lands Cooperative Study on the Adequacy of Dialysis was
designed to test the 2-year equivalence of HD and peritoneal
dialysis (PD) for incident ESRD patients.39 The total required
sample size was 100 subjects to be able to detect a 10-point
difference in quality-adjusted life years score. However, after
3 years, only 38 subjects had been recruited. Despite
unsuccessful enrollment, after adjustment for baseline
characteristics, no significant differences were found in the
2-year mean quality-adjusted life years score (3.1; 95% CI
9.9 to 16.1) or 5-year mortality (HD versus PD, HR 3.6;
95% CI 0.8–15.4). In this case, the inability to enroll enough
subjects dramatically affected the strength of the conclusions
that HD and PD yield equivalent outcomes.
STUDY DESIGN AND COMPARISON OF OUTCOMES
Interventional studies randomize subjects to different treat-
ment arms and compare outcomes. Randomization mini-
mizes, to the extent possible, the effects of known and
unknown confounders on the differences in outcomes
by attempting to equally distribute them between or among
arms. Another powerful design for randomized clinical
trials is the comparison of paired outcome data within
an individual. Using each subject as his or her own control
in the analysis of an intermediate outcome may reduce the
impact of individual variation due to severity of illness.
However, the death or dropout of subjects between
the baseline and follow-up measurements may result in
informative censoring. An example of both designs is the
Treat to Goal study, which randomized 200 prevalent dialysis
patients to sevelamer or calcium-based phosphate binders
to compare serum phosphorus, calcium, and parathyroid
hormone levels as the primary outcomes and coronary
and aortic calcification at baseline and 1 year as secondary
outcomes.40 Baseline calcification scores were obtained for
186 patients, but 1-year scores were available for only 71% of
initial cohort, and a total of 11 deaths occurred during the
course of the study. Although the mortality rate in this study
(55 deaths per 1000 patient-years) was relatively low as
compared with USRDS data, the extent to which it could
affect the results cannot be estimated. Longer trials with
dialysis patients selected to represent the national mortality
rate of 200–300 deaths per 1000 patient-years could be greatly
impacted.27 In CKD and ESRD patients with such high
mortality, pairing of outcomes may thus be problematic.
A perceived problem that is arguably no different from the
general population of studies is the perceived success of
randomization in equally distributing potential confounders
between or among treatment groups. When an unexpected
trial result is obtained, a failure of randomization is
a frequently cited limitation. However, our ability to
adequately identify and quantify the most important ‘known
predictors of mortality’ is arguably and unfortunately
limited. One cohort study of incident dialysis patients
demonstrated that age, comorbidity score, and functional
status captured only 28% of the log likelihood of 1-year
mortality.41 A study of prevalent dialysis patients, faring
slightly better, found that age, diabetic status, and assessment
of biopsychosocial care need explained 32–40% of the
variance in the mental and physical health components
of the SF-36 QOL survey.42 One of the best prediction
models, incorporating detailed comorbidity data, only
produced an area under the receiver–operator characteristics
curve of 0.77.43 These results suggest that many of the
predictors of clinical outcomes in ESRD patients are
unknown, and that our ability to judge whether they have
been equally distributed between treatment arms may be
difficult.
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CHOICE AND DETECTION OF END POINTS
Some end points clearly defined in the reference population
may be more difficult to determine in the CKD and ESRD
populations. Among these is the diagnosis of MI. Many CKD
patients have baseline elevations in cardiac troponins in the
absence of acute myocardial injury that, although correlating
with clinical outcomes, affect the ability to adjudicate acute
MI. In addition, electrolyte abnormalities, left ventricular
hypertrophy, and pericarditis can also affect electrocardio-
gram interpretation.44 Hospitalization for CHF is another
end point which, in its definition phase, generates much
discussion trying to balance the underlying pathophysiology
with the practicality of the clinical information that would
be available on a case basis. In CHOIR, CHF was defined as
an unplanned admission during which the subject received
intravenous inotropes, diuretics, or vasodilators.5 In contrast,
a study by Smith et al.45 in the Journal of Cardiac Failure
defined hospitalization for CHF as either a diagnosis of CHF
or a chest X-ray consistent with CHF on admission and
documentation of 15 possible signs and symptoms of CHF
within 3 days. Although variations between studies in the
definitions of end points do not invalidate individual results,
they certainly make assumptions and comparison of trials
difficult, potentially and erroneously predisposing some to be
concerned about the validity of results.
Changes in kidney function, as a study outcome, can also
be difficult to accurately assess. Serum creatinine-based
measurements of GFR may overestimate renal function if,
for example, a patient loses muscle mass after a stroke.
Although stroke is less common in CKD and ESRD patients,
even clinically unremarkable events, such as changes in
volume status or even taking creatine supplements or eating
cooked meat, can affect the serum creatine and may be
more common and under-recognized.46,47 Notwithstanding
the ability to accurately track kidney function, the use of
ESRD incidence as an outcome may also have limitations.
Although the National Kidney Foundation–Dialysis Out-
comes Quality Initiative guidelines recommend starting renal
replacement therapy in the GFR range of 10–15 ml/min/
1.73 m2, the point at which CKD becomes ESRD (that is,
when dialysis must be initiated) is sometimes subjective.
Individual patient factors, such as age, overall health,
symptoms that may be judged uremic, fluid balance, and
dietary and medication compliance must also be factored
into the decision.48 Underscoring the subjective and changing
practice patterns over time, the average GFR at dialysis
initiation in the USRDS database has increased from 7.5 to
10.1 ml/min/1.73 m2 over the past decade, demonstrating a
systematic change in objective factors that could mask this
outcome over time.27
Finally, hospitalization for dialysis access management in
ESRD patients is associated with major mortality and
morbidity. Investigators frequently struggle with whether to
include this event as an end point. Vascular access catheter-
related infection and sepsis occur at respective rates of
1.3 and 1.6 episodes per patient-year; rates are lower but still
significant for those with either arteriovenous grafts or
fistulae.27 HD patients are frequently admitted to undergo
catheter removal or arteriovenous access declotting or
angioplasty, and PD patients are often hospitalized for
episodes of peritonitis. ESRD patients are thus subject to
unique complications, and including assessments of access-
related hospitalizations during clinical trials would be
prudent to fully evaluate the benefits or harms of an
intervention. Careful consideration of how to handle the
complicated scenario of patients experiencing morbidity
or mortality following an access procedure and how these
events should be adjudicated need to be discussed and vetted
at both the individual trial level and potentially, and perhaps
more importantly, among the research community as a
whole.
Clearly, the most important clinical end points in
evaluating the benefits of therapy are mortality and major
morbidity. However, when the potential benefits of therapy
are initially being investigated, the use of intermediate out-
comes, with the caveat that they truly satisfy the McMaster
criteria as proper surrogates, may also be of value. For
example, the use of proteinuria and progression of CKD are
appropriate in selected nephrology trials, given their corre-
lation with renal survival. It is noteworthy that some
studies that have focused on such intermediate outcomes,
such as those demonstrating the effectiveness of angiotensin
receptor blockers in diabetic kidney disease, have had positive
results.49,50
ASSESSMENT OF QOL
As clinicians, our goals are to attempt to improve both the
quantity and QOL. Arguably, the comorbidities and treat-
ments of patients with CKD and ESRD affect their QOL
dramatically. Methodologically, however, studying QOL is
likely complicated by the high frequency of both functional
and organic psychiatric disorders in CKD and ESRD patients
that may affect the ability to identify and quantify a change in
QOL due to some form of treatment. A total of 3–8% of
ESRD patients carry the diagnosis of dementia, although
recent analysis suggests that cognitive impairment is present
in a staggering 87% of the ESRD population.51–53 How to
quantify the degree of cognitive impairment and how it
affects assessment of QOL is not entirely clear. Furthermore,
depression is also common, occurring at a rate of 84% in one
group of 380 PD patients.54 Although this last study
suggested that pharmacological therapy was associated with
improvement in the Beck Depression Inventory score, 38% of
patients who failed to improve had coexisting personality
disorders. It is not known how this high prevalence of
psychiatric comorbidity among the ESRD population affects
assessments of mental health or cognitive capacity in clinical
trials where diagnoses such as depression are not the focus,
but without attention, these conditions clearly would bias
findings toward the null.
Moreover, the instruments typically used to measure
QOL may have significant limitations when applied to ESRD
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patients.55 For example, commonly used depression inven-
tories may not be valid in the dialysis population. QOL
questionnaires are also frequently, and inappropriately, used
in countries other than those in which they were validated.
Lastly, QOL measured in different groups of patients, such as
those undergoing different types of renal replacement, are
often compared without standardization for age, gender, and
comorbidity, which would require the use of generic as well
as modality-specific instruments.
CONCLUSION
There are numerous methodological possibilities to address
the question of why so many trials in nephrology have had
negative or neutral results (see Figure 1). Many obstacles are
present in the optimal design of successful clinical trials in
nephrology (see Table 1). These problems include reliance on
observational data and extrapolation from the non-CKD
population in designing relevant study questions, healthy
volunteer effect during study recruitment, informative
censoring and unequal randomization in the study design,
lack of generalizability and insufficient numbers of partici-
pants, variability in definitions of clinical end points, and
inaccurate QOL assessment.
In some cases, well-established analytical techniques may
be helpful in overcoming some of these limitations. For
instance, imputation of missing values can be helpful in
dealing with informative censoring. Unequal randomization
is frequently addressed by adjusting outcome variables for
the parameters in question. Groups of trials that are
underpowered by insufficient participation may be consi-
dered collectively using meta-analysis.
Although these problems are not unique to nephrology
trials, we suggest a focus by nephrologists involved in clinical
research to examine lessons learned to improve the yield
of future trials in nephrology. The development, vetting,
and general acceptance of common principles to guide trial
design in nephrology studies would likely enhance our ability
to accomplish trials as well as compare results between trials.
If we consider and adopt methodological lessons learned, we
can minimize, but never eliminate, major concerns about the
impact of different design features on results and focus on
learning from positive, negative, and neutral trials.
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